Focus: Astellas is a 5,000+ employee biotechnology company headquartered in Shenyang, China, specializing in small molecules, ADCs, cell therapy, gene therapy, and antibodies across oncology and specialty care.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Astellas to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Astellas
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Astellas's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship product generating 96% of company revenue; androgen receptor antagonist with 13-year patent runway.
Secondary revenue driver in hematology with FLT3 selectivity; 8 active Phase 2 trials suggest development expansion.
ADC platform lead with 11 active trials indicating broad development strategy; emerging oncology franchise.
Newly approved neurokinin-3 receptor antagonist; 8 Phase 3 trials support label expansion in women's health.
Recently launched retinal complement inhibitor in high-demand orphan ophthalmology space; 2 Phase 4 trials ongoing.
33 discontinued, 9 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub